Size the destination market for an API you manufacture. Top destinations by USD, YoY growth, and how concentrated the incumbent exporter cohort is on each lane.
Losartan API moved $126.6M of declared trade in 2024 across 43 destinations. The US absorbs $61.6M (49% of the global pool) on a tight lane: 9 active exporters and the top-3 holding 83.3% share. Philippines and Iraq are the growth outliers, with Iraq surging from a near-zero base on rising domestic generics demand.
| # | Destination | Region | 2024 USD value | YoY 2023→2024 | Top-3 exporter share |
|---|---|---|---|---|---|
| 1 | United States | US · Tier-1 regulated | 62 $M | +42.0% YoY | Top-3 83.3% |
| 2 | Philippines | PH · Southeast Asia | 15 $M | +10.4% YoY | Top-3 76.4% |
| 3 | Sri Lanka | LK · South Asia | 8 $M | -1.5% YoY | Top-3 95.5% |
| 4 | Chile | CL · LatAm | 8 $M | +0.1% YoY | Top-3 92.1% |
| 5 | South Africa | ZA · Sub-Saharan | 4 $M | -3.5% YoY | Top-3 88.7% |
| 6 | United Kingdom | GB · EU-aligned | 4 $M | -3.8% YoY | Top-3 95.3% |
| 7 | Myanmar | MM · Southeast Asia | 4 $M | +21.8% YoY | Top-3 94.6% |
| 8 | Iraq | IQ · Middle East | 2 $M | +932% YoY | Top-3 99.0% |
Type the INN of an API you make or are evaluating. The AI agent matches against the molecule catalog and pulls every declared destination.
Total USD trade value per destination, YoY delta versus the prior year, and the active exporter cohort already serving the lane.
Citation-anchored leaderboard of destinations, ranked by value, with growth and entry-difficulty signals per row.
Declared trade value sums every shipment that cleared on the lane. Not survey panels, not modelled forecasts.
A $20M market growing 50% YoY is a different opportunity than a $100M market that flatlined. Both signals on one row.
Top-3 exporter share tells you which lanes are wide open and which already have an entrenched anchor exporter.
Trade aggregates flow in weekly. Sizing recomputes; the catalog row carries the exact computation timestamp.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Sample portfolio of cardiometabolic and CNS APIs · 2024 global declared trade value per molecule, in $M.
Market sizing for API manufacturers is the first question before any plant decision: where does my molecule actually clear, in what value, growing how fast, and how packed is the lane already. PharmaDB joins declared trade flows to the molecule catalog and to lane-level competitiveness, so a supplier sees the size, the trend, and the entry difficulty in a single brief. The view is molecule_country_flow; the join is to lane_competitiveness and molecules. Refresh cadence is weekly.
Declared trade value is summed across every shipment that cleared into the destination for the matched molecule, scoped to the year. The compute runs on `molecule_country_flow`. Outliers above 100x the lane median USD/kg are flagged out of the volume math but retained in the audit log.
Declared trade is the actual cargo that moved. It is the cleanest proxy for API demand because it is per-shipment, dated, and ties back to a buyer cohort. Panel data has fewer molecules and lags by quarters.
It is the entry-difficulty signal. A lane where the top-3 exporters hold 95% has an entrenched anchor and is hard to displace. A lane where the top-3 hold 60% has room for a credible new entrant. Both signals show on the row.
This view is API-only. The molecule catalog tags shipments by form (API, FDF, intermediate). FDF demand sizing is the companion analysis under the formulator pages.
Weekly. The trade warehouse refreshes every week and the sizing compute reruns on every refresh. The catalog row carries the exact computation timestamp.
Yes, with a flag. Re-export hubs (Singapore, Netherlands, UAE) are included so suppliers see the routing reality, but the AI agent surfaces a hub-tagged badge so the destination is not misread as an end-user market.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.